Free provider profile
THOMAS ANDREWS, M.D.
NPI 1245393651
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2011-10-03.
2891 CHURN CREEK RD, REDDING, CA, 96002
530-221-7474
Single practice location
Enumerated 2006-12-18
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 4 taxonomies listed — broader service mix.
- — Record last updated 15 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
2,483
Medicare patients
180
Part D drug cost
$271,325
Brand-name share
Not published
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Nuedexta (Dextromethorphan Hbr/Quinidine) | 12 | $18,604 |
| Mounjaro (Tirzepatide) | 12 | $12,664 |
| Belsomra (Suvorexant) | 20 | $8,504 |
| Desvenlafaxine Succinate Er (Desvenlafaxine Succinate) | 108 | $7,277 |
| Vyvanse (Lisdexamfetamine Dimesylate) | 15 | $5,770 |
| Clozapine (Clozapine) | 16 | $4,148 |
| Lisdexamfetamine Dimesylate (Lisdexamfetamine Dimesylate) | 14 | $2,669 |
| Mirtazapine (Mirtazapine) | 72 | $2,343 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024358 sessions · 16 patients · $328,455
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.